Edward M. MD Kaye - 27 Mar 2024 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
CEO, Director
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Issuer symbol
STOK
Transactions as of
27 Mar 2024
Transactions value $
$0
Form type
4
Date filed
07 Jun 2024, 16:42
Previous filing
19 Mar 2024
Next filing
16 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Employee Stock Option (Right to Buy) Award $0 +159K $0.00 159K 27 Mar 2024 Common Stock 159K $14.17 Direct F1
transaction STOK Restricted Stock Units Award $0 +105K $0.00 105K 27 Mar 2024 Common Stock 105K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested or vests as to 1/48 of the total award on April 15, 2024, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3 The award vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date.